Levels of C-peptide, body mass index and age, and their usefulness in classification of diabetes in relation to autoimmunity, in adults with newly diagnosed diabetes in Kronoberg, Sweden
Open Access
- 1 June 2012
- journal article
- research article
- Published by Oxford University Press (OUP) in Acta Endocrinologica
- Vol. 166 (6), 1021-1029
- https://doi.org/10.1530/eje-11-0797
Abstract
Objective: C-peptide is a main outcome measure in treatment trials of diabetes. C-peptide also has a role in the classification of diabetes, which is often difficult in adults and this is also increasingly recognised in adolescents and elders.Aim: We aimed to describe the levels of C-peptide in relation to age and body mass index (BMI) in a large population-based cohort of adults with newly diagnosed diabetes and compare the capabilities of C-peptide, age and BMI to discriminate between autoimmune and non-autoimmune diabetes.Subjects and methods: Blood samples from 1180 patients were analysed regarding islet cell antibody, glutamic acid decarboxylase antibody and fasting C-peptide (FCP). Receiver operating characteristics (ROC) curves were analysed to check the ability of age, BMI and C-peptide to discriminate between autoantibody-positive (Ab+) and -negative (Ab−) diabetes.Results: Mean FCP was 0.73±0.5 (range 0.13–1.80) nmol/l in the Ab+ and 1.42±0.9 (range 0.13–8.30) nmol/l in the Ab−. FCP was 0.02 nmol/l higher per year increase in age at diagnosis of diabetes. Mean BMI was 26.0±4.8 (range 18.0–39.0) kg/m2 in the Ab+ and 28.9±5.3 (range 15.5–62.6) kg/m2 in the Ab−. FCP increased with age also within each BMI group. The highest area under the curve (AUC) in the ROC analysis was found for C-peptide, followed by age and BMI (0.78, 0.68 and 0.66 respectively).Conclusions: At diagnosis of diabetes, C-peptide was superior to age and BMI in discriminating between autoimmune and non-autoimmune diabetes. C-peptide increased significantly with BMI and age, latter also within each BMI group. Most of the adults had normal or high levels of C-peptide at presentation of diabetes among the autoimmune patients.This publication has 45 references indexed in Scilit:
- β-cell function and metabolic control in latent autoimmune diabetes in adults with early insulin versus conventional treatment: a 3-year follow-upActa Endocrinologica, 2011
- Diagnosis and Classification of Diabetes MellitusDiabetes Care, 2010
- Islet Cell Antibody–Positive Versus –Negative Phenotypic Type 2 Diabetes in YouthDiabetes Care, 2009
- Goals of Treatment for Type 2 DiabetesDiabetes Care, 2009
- Preservation of β-Cell Function in Autoantibody-Positive Youth With DiabetesDiabetes Care, 2009
- Efficacy and Safety of the Human Glucagon-Like Peptide-1 Analog Liraglutide in Combination With Metformin and Thiazolidinedione in Patients With Type 2 Diabetes (LEAD-4 Met+TZD)Diabetes Care, 2009
- Gender differences in insulin resistance, body composition, and energy balanceGender Medicine, 2009
- Autoimmunity and clinical course in children with type 1, type 2, and type 1.5 diabetesJournal of Autoimmunity, 2005
- What Impact Would Pancreatic Beta-cell Preservation Have on Life Expectancy, Quality-adjusted Life Expectancy and Costs of Complications in Patients with Type 2 Diabetes? A Projection Using the CORE Diabetes ModelCurrent Medical Research and Opinion, 2004
- B-cell function and blood glucose control in insulin dependent diabetics within the first month of insulin treatmentDiabetologia, 1977